Literature DB >> 8194197

Central nervous system as sanctuary site of relapse in patients treated with chemotherapy for metastatic testicular cancer.

A Gerl1, C Clemm, P Kohl, A Schalhorn, W Wilmanns.   

Abstract

Isolated central nervous system relapse in patients treated successfully with cisplatin-based chemotherapy for testicular cancer has been described infrequently. In a retrospective analysis we identified this complication in six of 417 patients. Five of the six patients had advanced pulmonary dissemination at onset of chemotherapy, and post-chemotherapy surgery did not reveal viable tumour tissue in any of these cases. All six patients developed a single cerebral metastasis during complete remission a median four months after discontinuation of chemotherapy. Five patients were treated with surgery and subsequent radiotherapy, one patient with irradiation alone. Three patients are alive relapse-free 19, 62 and 86 months after diagnosis of cerebral relapse. One patient was alive with cerebral disease for 12 months without evidence of systemic recurrence. Our data demonstrate that the brain may act as a sanctuary site in chemotherapy-treated testicular cancer. A review of the literature shows that an isolated cerebral relapse is an extremely rare complication, but carries a relatively favourable prognosis.

Entities:  

Mesh:

Year:  1994        PMID: 8194197     DOI: 10.1007/bf01753890

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  21 in total

1.  Brain metastases in disseminated germinal neoplasms: incidence and clinical course.

Authors:  S D Williams; L H Einhorn
Journal:  Cancer       Date:  1979-10       Impact factor: 6.860

2.  Successful management of metastatic and primary germ cell tumors in the brain.

Authors:  G J Rustin; E S Newlands; K D Bagshawe; R H Begent; S M Crawford
Journal:  Cancer       Date:  1986-06-01       Impact factor: 6.860

3.  Prognostic factors in unselected patients with nonseminomatous metastatic testicular cancer: a multicenter experience.

Authors:  N Aass; O Klepp; E Cavallin-Stahl; O Dahl; H Wicklund; B Unsgaard; L Baldetorp; S Ahlström; S D Fosså
Journal:  J Clin Oncol       Date:  1991-05       Impact factor: 44.544

4.  Prognostic implications of tumour marker analysis in non-seminomatous germ cell tumours with poor prognosis metastatic disease.

Authors:  A Gerl; C Clemm; R Lamerz; K Mann; W Wilmanns
Journal:  Eur J Cancer       Date:  1993       Impact factor: 9.162

5.  Systemic chemotherapy for a primary germ cell tumor of the brain: a pharmacokinetic study.

Authors:  S Ginsberg; J Kirshner; S Reich; L Panasci; T Finkelstein; S Fandrich; A Fitzpatrick; L Shechtman; R Comis
Journal:  Cancer Treat Rep       Date:  1981 May-Jun

6.  Brain metastasis as the site of relapse in germ cell tumor of testis.

Authors:  V Raina; S P Singh; N Kamble; R Tanwar; K Rao; R Dawar; G K Rath
Journal:  Cancer       Date:  1993-10-01       Impact factor: 6.860

7.  Sanctuary site relapse in chemotherapy-treated testicular cancer.

Authors:  P P James; G M Mead
Journal:  Ann Oncol       Date:  1992-01       Impact factor: 32.976

8.  Cis-diamminedichloroplatinum, vinblastine, and bleomycin combination chemotherapy in disseminated testicular cancer.

Authors:  L H Einhorn; J Donohue
Journal:  Ann Intern Med       Date:  1977-09       Impact factor: 25.391

9.  Vinblastine-ifosfamide-cisplatin treatment of bulky seminoma.

Authors:  C Clemm; R Hartenstein; N Willich; L Boening; W Wilmanns
Journal:  Cancer       Date:  1986-11-15       Impact factor: 6.860

10.  Salvage treatment in male patients with germ cell tumours.

Authors:  D Josefsen; S Ous; J Høie; A E Stenwig; S D Fosså
Journal:  Br J Cancer       Date:  1993-03       Impact factor: 7.640

View more
  8 in total

1.  Brain metastasis from non-seminomatous germ cell tumors of the testis: indications for aggressive treatment.

Authors:  Maurizio Salvati; Manolo Piccirilli; Antonino Raco; Antonino Santoro; Riccardo Frati; Jacopo Lenzi; Gaetano Lanzetta; Antonino Agrillo; Alessandro Frati
Journal:  Neurosurg Rev       Date:  2005-11-23       Impact factor: 3.042

Review 2.  Brain metastases: 1995. A brief review.

Authors:  J B Posner
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

3.  Synchronous versus metachronous brain metastasis from testicular germ cell tumors (TGCT): an analysis from the Spanish Germ Cell Cancer Group data base.

Authors:  R Girones; J Aparicio; P Roure; J R Germa-Lluch; X García Del Muro; S Vazquez-Estevez; A Saenz; J Sastre; J Arranz Arija; E Gallardo; E Gonzalez-Billalabeitia; A Sanchez-Hernandez; J Terrasa; A Hernandez; C Santander; E Cillan; N Sagastibelza; D Almenar-Cubells; M Lopez Brea; J P Maroto
Journal:  Clin Transl Oncol       Date:  2014-04-10       Impact factor: 3.405

Review 4.  Malignant germ cell tumors metastatic to the brain: a model for a curable neoplasm? The Freiburg experience and a review of the literature.

Authors:  Johannes Lutterbach; Uwe Spetzger; Susanne Bartelt; Axel Pagenstecher
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

5.  Gamma knife radiosurgery in brain metastases from testicular tumors.

Authors:  A Nicolato; A Ria; R Foroni; P Manno; F Alessandrini; T Sava; F Lupidi; P Leone; S Maluta; G L Cetto; M Gerosa
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 6.  Transitional cell carcinoma presenting as a solitary brain lesion: a case report and review of the world literature.

Authors:  R E Clatterbuck; P Sampath; A Olivi
Journal:  J Neurooncol       Date:  1998-08       Impact factor: 4.130

7.  Prognosis after salvage treatment for unselected male patients with germ cell tumours.

Authors:  A Gerl; C Clemm; N Schmeller; R Hartenstein; R Lamerz; W Wilmanns
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

8.  Sequential resection of residual abdominal and thoracic masses after chemotherapy for metastatic non-seminomatous germ cell tumours.

Authors:  A Gerl; C Clemm; N Schmeller; H Dienemann; M Weiss; M Kriegmair; U Löhrs; W Wilmanns
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.